ANI Pharmaceuticals
ANIP
205 hedge funds and large institutions have $1.07B invested in ANI Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 69 increasing their positions, 60 reducing their positions, and 31 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 60
1.89% more ownership
Funds ownership: 89.96% → 91.85% (+1.9%)
0% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 31
1% less funds holding
Funds holding: 208 → 205 (-3)
6% less capital invested
Capital invested by funds: $1.14B → $1.07B (-$71.7M)
69% less call options, than puts
Call options by funds: $188K | Put options by funds: $597K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$27.2M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17.7M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$13.7M |
| 4 |
SCM
Sio Capital Management
New York
|
+$9.19M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$32.5M |
| 2 |
JP Morgan Chase
New York
|
-$16.5M |
| 3 |
Morgan Stanley
New York
|
-$10M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$9.34M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$7.61M |
ANIP Hedge Fund Activity: Q4 2024 in Review
205 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q4 2024, worth a combined $1.07B — down 6.3% from $1.14B a quarter earlier.
Fund positioning in ANIP was balanced in Q4 2024: 31 funds opened new positions, 31 closed out, 69 added to existing stakes and 60 trimmed.
The largest buyer was Millennium Management, adding an estimated $27.2M. The largest seller was Pacer Advisors, cutting an estimated $32.5M.
- 205 institutional investors held ANI Pharmaceuticals (ANIP) as of Q4 2024, down from 208 in Q3 2024.
- Funds reported $1.07B of ANI Pharmaceuticals stock for Q4 2024, down 6.3% quarter-over-quarter.
- 31 funds opened new ANI Pharmaceuticals positions in Q4 2024 and 31 closed out, a net change of 0 holders.
- The largest ANI Pharmaceuticals buyer in Q4 2024 was Millennium Management, an estimated $27.2M added.
- The largest ANI Pharmaceuticals seller in Q4 2024 was Pacer Advisors, an estimated $32.5M sold.
Based on aggregated 13F filings for Q4 2024.